The Relative Strength (RS) Rating for Ligand Pharmaceuticals climbed into a new percentile Tuesday, with a rise from 78 to 82.
Hone Your Stock-Picking Skills By Focusing On These Factors
This exclusive rating from Investor's Business Daily measures price action with a 1 (worst) to 99 (best) score. The rating shows how a stock's price behavior over the last 52 weeks holds up against all the other stocks in our database.
Over 100 years of market history reveals that the top-performing stocks often have an RS Rating north of 80 as they launch their biggest price moves.
Ligand Pharmaceuticals is working on a consolidation with a 129.90 entry. See if it can clear the breakout price in volume at least 40% above average. Note that it's a third-stage base. Later-stage patterns can work, but have a higher chance of failing since, by that point, the stock has already made a significant climb..
The company reported -65% EPS growth last quarter, while sales growth came in at 46%. Keep an eye out for the company's next round of numbers on or around Aug. 11.
Ligand Pharmaceuticals earns the No. 12 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, TG Therapeutics and Inhibrx Biosciences are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Improved Price Performance?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
